{"protocolSection":{"identificationModule":{"nctId":"NCT00718237","orgStudyIdInfo":{"id":"V260-029"},"secondaryIdInfos":[{"id":"2008_014"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)","officialTitle":"A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of V260 in Healthy Infants in Japan"},"statusModule":{"statusVerifiedDate":"2017-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-08"},"primaryCompletionDateStruct":{"date":"2009-08","type":"ACTUAL"},"completionDateStruct":{"date":"2009-08","type":"ACTUAL"},"studyFirstSubmitDate":"2008-07-16","studyFirstSubmitQcDate":"2008-07-16","studyFirstPostDateStruct":{"date":"2008-07-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-06-23","resultsFirstSubmitQcDate":"2010-06-23","resultsFirstPostDateStruct":{"date":"2010-07-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-03-16","lastUpdatePostDateStruct":{"date":"2017-04-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate whether V260 is effective and well tolerated in Japanese healthy infants."},"conditionsModule":{"conditions":["Rotavirus","Gastroenteritis"],"keywords":["Gastroenteritis","Rotavirus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":762,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"RotaTeq™","interventionNames":["Biological: Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)"]},{"label":"2","type":"PLACEBO_COMPARATOR","description":"Placebo","interventionNames":["Biological: Comparator: Comparator: Placebo (unspecified)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)","description":"Rotateq orally administered 3 times","armGroupLabels":["1"],"otherNames":["RotaTeq™","V260"]},{"type":"BIOLOGICAL","name":"Comparator: Comparator: Placebo (unspecified)","description":"Placebo orally administered 3 times","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Rotavirus Gastroenteritis of Any Severity Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A","description":"Any severity cases of rotavirus gastroenteritis caused by G1, G2, G3, G4 or G-serotypes associated with serotype P1A occurring at least 14 days postdose 3 in the per-protocol population using per-protocol case definition","timeFrame":"At least 14 days following the 3rd vaccination"}],"secondaryOutcomes":[{"measure":"Number of Participants With Moderate to Severe Rotavirus Gastroenteritis Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A","description":"Moderate to severe cases of rotavirus gastroenteritis caused by G1, G2, G3, G4 or G-serotypes associated with serotype P1A occurring at least 14 days postdose 3 in the per-protocol population using per-protocol case definition. Severity score was calculated based on frequency and duration of diarrhea, vomiting, elevated temperature, and behavioral changes. Score of \\>8 and \\<=16 was considered moderate, and \\>16 was considered severe.","timeFrame":"At least 14 days following the 3rd vaccination"},{"measure":"Number of Participants With Severe Rotavirus Gastroenteritis Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A","description":"Severe cases of rotavirus gastroenteritis caused by G1, G2, G3, G4 or G-serotypes associated with serotype P1A occurring at least 14 days postdose 3 in the per-protocol population using per-protocol case definition. Severity score was calculated based on frequency and duration of diarrhea, vomiting, elevated temperature, and behavioral changes. Score of \\>8 and \\<=16 was considered moderate, and \\>16 was considered severe.","timeFrame":"At least 14 days following the 3rd vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy Japanese Infants, 6 Weeks Through 12 Weeks Of Age\n\nExclusion Criteria:\n\n* History Of Known Prior Rotavirus Gastroenteritis\n* Subjects Who Are Concurrently Participating In Or Are Anticipated To Participate In Other Studies Of Investigational Products At Any Time During The Study Period","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"23732903","type":"RESULT","citation":"Iwata S, Nakata S, Ukae S, Koizumi Y, Morita Y, Kuroki H, Tanaka Y, Shizuya T, Schodel F, Brown ML, Lawrence J. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Hum Vaccin Immunother. 2013 Aug;9(8):1626-33. doi: 10.4161/hv.24846. Epub 2013 May 31."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final\\_Updated%20July\\_9\\_2014.pdf\n\nhttp://engagezone.msd.com/ds\\_documentation.php"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Excluded from the trial before assignment to groups were subjects with: history of congenital abdominal\n\ndisorders, intussusception, or abdominal surgery; history of known prior rotavirus disease, chronic diarrhea,\n\nor failure to thrive; immune impairment or resides in a household with an individual with an immune impairment.","recruitmentDetails":"The study was conducted at 32 sites in Japan from 2008 to 2009.","groups":[{"id":"FG000","title":"RotaTeq™","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with 14 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) until the end of the study."},{"id":"FG001","title":"Placebo","description":"Three doses of placebo matching RotaTeq™ administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for AGEs until the end of the study."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Subjects who passed all entry criteria and who were randomized into the study","numSubjects":"381"},{"groupId":"FG001","comment":"Subjects who passed all entry criteria and who were randomized into the study","numSubjects":"381"}]},{"type":"Vaccinated at Visit 1","achievements":[{"groupId":"FG000","numSubjects":"380"},{"groupId":"FG001","numSubjects":"381"}]},{"type":"Vaccinated at Visit 2","achievements":[{"groupId":"FG000","numSubjects":"373"},{"groupId":"FG001","numSubjects":"374"}]},{"type":"Vaccinated at Visit 3","achievements":[{"groupId":"FG000","numSubjects":"371"},{"groupId":"FG001","numSubjects":"369"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Subjects who continued follow-up until the last visit, regardless of number of vaccinations received","numSubjects":"368"},{"groupId":"FG001","comment":"Subjects who continued follow-up until the last visit, regardless of number of vaccinations received","numSubjects":"366"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"15"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"10"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"RotaTeq™","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with 14 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) until the end of the study."},{"id":"BG001","title":"Placebo","description":"Three doses of placebo matching RotaTeq™ administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for AGEs until the end of the study."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"381"},{"groupId":"BG001","value":"381"},{"groupId":"BG002","value":"762"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Weeks","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7.6","spread":"1.7"},{"groupId":"BG001","value":"7.5","spread":"1.6"},{"groupId":"BG002","value":"7.5","spread":"1.6"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"6 to 12 Weeks of age","categories":[{"measurements":[{"groupId":"BG000","value":"381"},{"groupId":"BG001","value":"381"},{"groupId":"BG002","value":"762"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"173"},{"groupId":"BG001","value":"182"},{"groupId":"BG002","value":"355"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"208"},{"groupId":"BG001","value":"199"},{"groupId":"BG002","value":"407"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants With Moderate to Severe Rotavirus Gastroenteritis Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A","description":"Moderate to severe cases of rotavirus gastroenteritis caused by G1, G2, G3, G4 or G-serotypes associated with serotype P1A occurring at least 14 days postdose 3 in the per-protocol population using per-protocol case definition. Severity score was calculated based on frequency and duration of diarrhea, vomiting, elevated temperature, and behavioral changes. Score of \\>8 and \\<=16 was considered moderate, and \\>16 was considered severe.","populationDescription":"Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., protocol violators, unevaluable due to detection of wild-type rotavirus in stool prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants","timeFrame":"At least 14 days following the 3rd vaccination","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for AGEs until the end of the study."},{"id":"OG001","title":"Placebo","description":"Three doses of placebo matching RotaTeq™ administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for AGEs until the end of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"356"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","lowerLimit":"47.4","upperLimit":"94.1"},{"groupId":"OG001","value":"25"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Hypothesis: Efficacy \\>0%. Based on p\\< 1/(1+k); p = proportion of participants with outcome in vaccine group relative to total number of subjects with outcome; k = ratio of follow-up time; placebo/vaccine. Based on conditional binomial approach.","statisticalMethod":"Exact Conditional Test","statisticalComment":"Exact Conditional Test based on Binomial Distribution","paramType":"Vaccine Efficacy (1-Relative Risk [RR])","paramValue":"80.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"47.4","ciUpperLimit":"94.1","estimateComment":"Efficacy = 1-RR, expressed as a percentage; the RR is the incidence in the vaccine group / the incidence in the placebo group, adjusted for the ratio of the follow-up period in each group."}]},{"type":"PRIMARY","title":"Number of Participants With Rotavirus Gastroenteritis of Any Severity Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A","description":"Any severity cases of rotavirus gastroenteritis caused by G1, G2, G3, G4 or G-serotypes associated with serotype P1A occurring at least 14 days postdose 3 in the per-protocol population using per-protocol case definition","populationDescription":"Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., protocol violators, unevaluable due to detection of wild-type rotavirus in stool prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants","timeFrame":"At least 14 days following the 3rd vaccination","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) until the end of the study."},{"id":"OG001","title":"Placebo","description":"Three doses of placebo matching RotaTeq™ administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for AGEs until the end of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"356"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","lowerLimit":"39.9","upperLimit":"90.6"},{"groupId":"OG001","value":"27"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Hypothesis: Efficacy \\>0%. Based on p\\< 1/(1+k); p = proportion of participants with outcome in vaccine group relative to total number of subjects with outcome; k = ratio of follow-up time; placebo/vaccine. Based on conditional binomial approach.","statisticalMethod":"Exact Conditional Test","statisticalComment":"Exact Conditional Test based on Binomial Distribution","paramType":"Vaccine Efficacy (1-Relative Risk [RR])","paramValue":"74.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"39.9","ciUpperLimit":"90.6","estimateComment":"Efficacy = 1-RR, expressed as a percentage; the RR is the incidence in the vaccine group / the incidence in the placebo group, adjusted for the ratio of the follow-up period in each group."}]},{"type":"SECONDARY","title":"Number of Participants With Severe Rotavirus Gastroenteritis Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A","description":"Severe cases of rotavirus gastroenteritis caused by G1, G2, G3, G4 or G-serotypes associated with serotype P1A occurring at least 14 days postdose 3 in the per-protocol population using per-protocol case definition. Severity score was calculated based on frequency and duration of diarrhea, vomiting, elevated temperature, and behavioral changes. Score of \\>8 and \\<=16 was considered moderate, and \\>16 was considered severe.","populationDescription":"Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., protocol violators, unevaluable due to detection of wild-type rotavirus in stool antigen prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants","timeFrame":"At least 14 days following the 3rd vaccination","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for AGEs until the end of the study."},{"id":"OG001","title":"Placebo","description":"Three doses of placebo matching RotaTeq™ administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for AGEs until the end of the study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"355"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"55.4","upperLimit":"100.0"},{"groupId":"OG001","value":"10"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Hypothesis: Efficacy \\>0%. Based on p\\< 1/(1+k); p = proportion of participants with outcome in vaccine group relative to total number of subjects with outcome; k = ratio of follow-up time; placebo/vaccine. Based on conditional binomial approach.","statisticalMethod":"Exact Conditional Test","statisticalComment":"Exact Conditional Test based on Binomial Distribution","paramType":"Vaccine Efficacy (1-Relative Risk [RR])","paramValue":"100.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55.4","ciUpperLimit":"100.0","estimateComment":"Efficacy = 1-RR, expressed as a percentage; the RR is the incidence in the vaccine group / the incidence in the placebo group, adjusted for the ratio of the follow-up period in each group."}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"14-day period following each vaccination. Any death, Vaccine related SAE and Intussusception were collected during the study period.","description":"Parents/guardians were asked to record AEs on a standardized Vaccine Report Card (VRC) during 14 days after each vaccination. Solicited AEs included diarrhea and vomiting. Temperature was also measured daily for 7 days after each vaccination.\n\nThe number of patients listed \"At Risk\" is the number of patients who received study treatment.","eventGroups":[{"id":"EG000","title":"RotaTeq™","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with 14 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) until the end of the study.","seriousNumAffected":7,"seriousNumAtRisk":380,"otherNumAffected":179,"otherNumAtRisk":380},{"id":"EG001","title":"Placebo","description":"Three doses of placebo matching RotaTeq™ administered 28 to 70 days apart, with 14 days of follow-up after each vaccination, and follow-up for AGEs until the end of the study.","seriousNumAffected":9,"seriousNumAtRisk":381,"otherNumAffected":175,"otherNumAtRisk":381}],"seriousEvents":[{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Congenital absence of bile ducts","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":380},{"groupId":"EG001","numAffected":0,"numAtRisk":381}]},{"term":"Bronchitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":380},{"groupId":"EG001","numAffected":0,"numAtRisk":381}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Meningitis coxsackie viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":380},{"groupId":"EG001","numAffected":0,"numAtRisk":381}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":380},{"groupId":"EG001","numAffected":0,"numAtRisk":381}]},{"term":"Respiratory syncytial virus bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":380},{"groupId":"EG001","numAffected":0,"numAtRisk":381}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Infantile spasms","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Psychomotor retardation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Asphyxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":380},{"groupId":"EG001","numAffected":0,"numAtRisk":381}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]},{"term":"Dermatitis atopic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":1,"numAtRisk":381}]}],"otherEvents":[{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":380},{"groupId":"EG001","numAffected":3,"numAtRisk":381}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":380},{"groupId":"EG001","numAffected":7,"numAtRisk":381}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":380},{"groupId":"EG001","numAffected":47,"numAtRisk":381}]},{"term":"Infantile spitting up","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":380},{"groupId":"EG001","numAffected":2,"numAtRisk":381}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":380},{"groupId":"EG001","numAffected":29,"numAtRisk":381}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":380},{"groupId":"EG001","numAffected":31,"numAtRisk":381}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":380},{"groupId":"EG001","numAffected":8,"numAtRisk":381}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":380},{"groupId":"EG001","numAffected":14,"numAtRisk":381}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":380},{"groupId":"EG001","numAffected":37,"numAtRisk":381}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":380},{"groupId":"EG001","numAffected":2,"numAtRisk":381}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":380},{"groupId":"EG001","numAffected":8,"numAtRisk":381}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":380},{"groupId":"EG001","numAffected":9,"numAtRisk":381}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":380},{"groupId":"EG001","numAffected":4,"numAtRisk":381}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":380},{"groupId":"EG001","numAffected":8,"numAtRisk":381}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":380},{"groupId":"EG001","numAffected":6,"numAtRisk":381}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":380},{"groupId":"EG001","numAffected":16,"numAtRisk":381}]},{"term":"Dermatitis diaper","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":380},{"groupId":"EG001","numAffected":6,"numAtRisk":381}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":380},{"groupId":"EG001","numAffected":12,"numAtRisk":381}]},{"term":"Eczema infantile","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":380},{"groupId":"EG001","numAffected":10,"numAtRisk":381}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":380},{"groupId":"EG001","numAffected":4,"numAtRisk":381}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Japan"]},"conditionBrowseModule":{"meshes":[{"id":"D005759","term":"Gastroenteritis"}],"ancestors":[{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D004066","term":"Digestive System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D022243","term":"Rotavirus Vaccines"},{"id":"C492535","term":"RotaTeq"}],"ancestors":[{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}